Michael F Flessner
Overview
Explore the profile of Michael F Flessner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
1967
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raphael K, Isakova T, Ix J, Raj D, Wolf M, Fried L, et al.
J Am Soc Nephrol
. 2019 Dec;
31(1):161-174.
PMID: 31848294
Background: Oral sodium bicarbonate (NaHCO) may preserve kidney function in CKD, even if initiated when serum bicarbonate concentration is normal. Adequately powered trials testing this hypothesis have not been conducted,...
2.
Ix J, Isakova T, Larive B, Raphael K, Raj D, Cheung A, et al.
J Am Soc Nephrol
. 2019 May;
30(6):1096-1108.
PMID: 31085679
Background: Higher serum phosphate and fibroblast growth factor-23 (FGF23) levels may be modifiable to prevent cardiovascular disease in CKD. Short-term studies have reported modest efficacy in phosphate and FGF23 reduction...
3.
Flessner M
Pleura Peritoneum
. 2019 Mar;
1(4):183-191.
PMID: 30911622
Intraperitoneal chemotherapy has demonstrated significant pharmacologic and clinical advantage over traditional intravenous administration for cancers that are restricted to the peritoneal cavity. The combination of cytoreductive surgery with hyperthermic intraperitoneal...
4.
Mariani L, Bomback A, Canetta P, Flessner M, Helmuth M, Hladunewich M, et al.
Am J Kidney Dis
. 2018 Nov;
73(2):218-229.
PMID: 30420158
Rationale & Objectives: Glomerular diseases, including minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and immunoglobulin A (IgA) nephropathy, share clinical presentations, yet result from multiple biological mechanisms. Challenges to...
5.
Stachowska-Pietka J, Poleszczuk J, Flessner M, Lindholm B, Waniewski J
Nephrol Dial Transplant
. 2018 Nov;
34(5):864-870.
PMID: 30403818
Background: Ultrafiltration failure (UFF) in peritoneal dialysis (PD) patients is due to altered peritoneal transport properties leading to reduced capacity to remove excess water. Here, with the aim to establish...
6.
Dad T, Abebe K, Bae K, Comer D, Torres V, Czarnecki P, et al.
Kidney Int Rep
. 2018 Jun;
3(3):619-624.
PMID: 29854969
Introduction: The high burden of cardiovascular morbidity and mortality in autosomal dominant polycystic kidney disease (ADPKD) is related to development of hypertension and left ventricular hypertrophy. Blood pressure reduction has...
7.
Brosnahan G, Abebe K, Moore C, Bae K, Braun W, Chapman A, et al.
Curr Hypertens Rev
. 2018 Mar;
14(1):39-47.
PMID: 29564978
Background: The HALT PKD trial in early autosomal dominant polycystic kidney disease (ADPKD) showed that intensive control of systolic blood pressure to 95-110 mmHg was associated with a 14% slower...
8.
Mwasongwe S, Fulop T, Katz R, Musani S, Sims M, Correa A, et al.
J Clin Hypertens (Greenwich)
. 2018 Feb;
20(4):775-783.
PMID: 29450959
Whether elevated uric acid (UA) is an independent risk factor for chronic kidney disease (CKD) is not well established. The authors evaluated the relationship of UA with rapid kidney function...
9.
Brosnahan G, Abebe K, Moore C, Rahbari-Oskoui F, Bae K, Grantham J, et al.
Am J Kidney Dis
. 2018 Jan;
71(5):666-676.
PMID: 29306517
Background: Previous clinical studies of autosomal dominant polycystic kidney disease (ADPKD) reported that loss of kidney function usually follows a steep and relentless course. A detailed examination of individual patterns...
10.
Yu A, Shen C, Landsittel D, Harris P, Torres V, Mrug M, et al.
Kidney Int
. 2018 Jan;
93(3):691-699.
PMID: 29290310
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive enlargement of kidney cysts leading to chronic kidney disease (CKD) and end-stage renal disease (ESRD). Identification of an early biomarker...